Mucopoietic activity of zolimidine: is its effect through cellular turnover or by modification of the gastric mucosal blood flow?
Zolimidine 2-(methylsulphonyl-phenyl)-imidazo-(1,2-a)pyridine produces a high percentage of healing of gastro-duodenal ulcers. The action of the drug develops through an increase of protective factors on the gastric mucosal barrier. This study has the purpose of evaluating if the action of the drug is also mediated by microvascular factors. The analysis of the values of BAO, MAO and PAO confirmed that treatment with zolimidine does not modify gastric acid secretion; the values of the Neutral Red clearance at PAO, before and after the treatment, do not show a statistically significant variation of the gastric mucosal blood flow. According to the most recent literature, the increase of the gastric mucopoietic activity is carried out by a direct cellular action.
D000328:Adult; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000098:blood supply / Q000187:drug effects*; D006801:Humans; D008297:Male; D009499:Neutral Red / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology*
D011725:Pyridines; D009499:Neutral Red